Tracer library / [177Lu]Lu-HA-DOTATATE
[177Lu]Lu-HA-DOTATATE
Also written as [Lu-177]Lu-HA-DOTATATE; Lu-177-HA-DOTATATE
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Radiation induced lymphopenia during PRRT: Incidence, course, predictive factors, and association with overall survival.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals.2025 · Cancers (Basel) · Clinical study
- Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.2025 · Clin Nucl Med · Clinical study
- Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy.2024 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [177Lu]Lu-HA-DOTATATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 27090254: 'HA-DOTA-TATE (PiChem, Graz, Austria)'. Stage set/updated at stage 39 from PMID 39448269: 'In this study, we assessed the safety and efficacy of intraarterial PRRT in patients with advanced, progressive meningioma.'.